Efficacy of cannabinoids compared to the current standard treatments on symptom relief in persons with multiple sclerosis (CANSEP trial): study protocol for a randomized clinical trial.

MLA

Zertal, Amel, et al. “Efficacy of Cannabinoids Compared to the Current Standard Treatments on Symptom Relief in Persons with Multiple Sclerosis (CANSEP Trial): Study Protocol for a Randomized Clinical Trial.” Frontiers in Neurology, Aug. 2024, pp. 1–10. EBSCOhost, https://doi.org/10.3389/fneur.2024.1440678.

APA

Zertal, A., Alami Marrouni, K., Arbour, N., Jutras-Aswad, D., Pomey, M.-P., Rouleau, I., Prat, A., Larochelle, C., Beaulieu, P., Chamelian, L., Sylvestre, M.-P., Morin, D., Ouellette, J.-S., Fréjeau, N., & Duquette, P. (2024). Efficacy of cannabinoids compared to the current standard treatments on symptom relief in persons with multiple sclerosis (CANSEP trial): study protocol for a randomized clinical trial. Frontiers in Neurology, 1–10. https://doi.org/10.3389/fneur.2024.1440678

Chicago

Zertal, Amel, Kanza Alami Marrouni, Nathalie Arbour, Didier Jutras-Aswad, Marie-Pascale Pomey, Isabelle Rouleau, Alexandre Prat, et al. 2024. “Efficacy of Cannabinoids Compared to the Current Standard Treatments on Symptom Relief in Persons with Multiple Sclerosis (CANSEP Trial): Study Protocol for a Randomized Clinical Trial.” Frontiers in Neurology, August, 1–10. doi:10.3389/fneur.2024.1440678.